<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonvertebral osteomyelitis in adults: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonvertebral osteomyelitis in adults: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nonvertebral osteomyelitis in adults: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Osmon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron J Tande, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1389995099"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment of osteomyelitis includes consideration of issues related to debridement, management of infected foreign bodies (if present), antibiotic selection, and duration of therapy; these issues are discussed in the following sections.</p><p>General issues related to treatment of osteomyelitis are discussed here. Issues related to clinical manifestations and diagnosis of osteomyelitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p>Issues related to treatment of vertebral osteomyelitis, osteomyelitis associated with trauma, pelvic and sacral osteomyelitis, and prosthetic joint infection are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7659.html" rel="external">"Osteomyelitis associated with open fractures in adults"</a> and  <a class="medical medical_review" href="/z/d/html/14007.html" rel="external">"Pelvic osteomyelitis and other infections of the bony pelvis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p>Issues related to osteomyelitis in children are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6067.html" rel="external">"Hematogenous osteomyelitis in children: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">"Hematogenous osteomyelitis in children: Management"</a>.)</p><p class="headingAnchor" id="H3526575772"><span class="h1">CLINICAL APPROACH</span></p><p class="headingAnchor" id="H763045634"><span class="h2">Nonhematogenous osteomyelitis</span></p><p class="headingAnchor" id="H1816527153"><span class="h3">Absence of orthopedic hardware</span><span class="headingEndMark"> — </span>In general, management of osteomyelitis (in the absence of orthopedic hardware) consists of operative debridement followed by antimicrobial therapy for eradication of infection. </p><p>There may be a role for antimicrobial therapy alone (in the absence of surgical debridement) for carefully selected patients with diabetic foot osteomyelitis. In observational studies, success rates for treatment of diabetic foot osteomyelitis with antimicrobial therapy alone range from 64 to 82 percent [<a href="#rid1">1-3</a>]. In one small randomized trial including 37 patients treated with antibiotics alone for three months or surgical debridement and antibiotics for ten days, there was no difference in healing between the two groups [<a href="#rid4">4</a>]. However, patients with common comorbid conditions (such as arterial disease, Charcot arthropathy, and poorly controlled diabetes) were excluded. The role of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> as adjunctive therapy to reduce the likelihood of amputation in diabetic foot osteomyelitis remains unclear; meta-analyses and large randomized clinical trials are underway [<a href="#rid5">5-7</a>].</p><p class="headingAnchor" id="H3765014249"><span class="h4">Surgical debridement</span><span class="headingEndMark"> — </span>Surgical debridement for management of osteomyelitis consists of removal of necrotic material and culture of involved tissue and bone. A satisfactory soft tissue envelope overlying the site of infection must be re-established for successful treatment, either via direct closure or flap coverage.</p><p>In the setting of dead or injured bone and/or infected fluid collections, surgical debridement (and revascularization, in some cases) is a cornerstone of therapy. Antimicrobial therapy alone is not effective for cure of infected, necrotic bone. In addition, antibiotic penetration into bone may be unreliable in patients with arterial insufficiency or prior scarring associated with trauma [<a href="#rid8">8</a>].</p><p>Surgical debridement also allows placement of local antimicrobials, either applied directly to the site of infection or mixed with absorbable (eg, calcium sulfate) or nonabsorbable (eg, polymethyl methacrylate cement) carriers. (See  <a class="medical medical_review" href="/z/d/html/8175.html" rel="external">"Management of diabetic foot ulcers"</a> and  <a class="medical medical_review" href="/z/d/html/7659.html" rel="external">"Osteomyelitis associated with open fractures in adults"</a>.)</p><p>Patients who have received antibiotics recently and do not have an acute need for surgical intervention should discontinue antibiotics for at least two weeks prior to debridement to optimize microbiologic diagnosis. However, patients with necrotizing soft tissue infection or with systemic infection secondary to osteomyelitis in whom source control is needed should undergo early surgical debridement.</p><p class="headingAnchor" id="H3688776889"><span class="h4">Antibiotic therapy</span><span class="headingEndMark"> — </span>The clinical approach to antibiotic therapy is discussed in this section; issues related to selection of antibiotic therapy are discussed below. (See <a class="local">'Antibiotic therapy'</a> below.)</p><p class="headingAnchor" id="H314760489"><span class="h5">Residual infected bone present</span><span class="headingEndMark"> — </span>Patients with residual infected bone that is not amenable to complete removal should be treated with a prolonged duration of intravenous or highly bioavailable oral antibiotic therapy, guided by antimicrobial susceptibility data. (See <a class="local">'Antibiotic therapy'</a> below.)</p><p>The optimal duration of antibiotic therapy for treatment of osteomyelitis with residual infected bone is uncertain. Most experts favor continuing antimicrobial therapy at least until debrided bone has been covered by vascularized soft tissue, which is usually at least six weeks from the last debridement [<a href="#rid9">9</a>]. Further studies are ongoing to define whether a shorter duration of therapy is equally effective [<a href="#rid10">10-12</a>]. Parenteral antimicrobial therapy can be administered on an outpatient basis via a peripherally inserted central catheter or similar device. In some circumstances, highly bioavailable oral antibiotic therapy may be administered.</p><p>While on parenteral antimicrobial therapy, patients should have weekly bloodwork for safety monitoring. (See <a class="local">'Monitoring during treatment'</a> below.)</p><p class="headingAnchor" id="H3855438131"><span class="h5">No residual infected bone</span><span class="headingEndMark"> — </span>Patients who undergo amputation or complete removal of all involved bone warrant a relatively short course of antibiotic therapy (see <a class="local">'Antibiotic therapy'</a> below). In the absence of concomitant soft tissue infection, antibiotic therapy may be discontinued as early as two to five days after debridement. When there is evidence of soft tissue infection at the operative site, 10 to 14 days of pathogen-directed parenteral or highly bioavailable oral therapy is reasonable [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H4291210690"><span class="h3">Presence of orthopedic hardware</span></p><p class="headingAnchor" id="H3730943096"><span class="h4">Surgical debridement</span><span class="headingEndMark"> — </span>In general, the approach to management of osteomyelitis associated with orthopedic hardware consists of operative debridement, obtaining bone biopsy for culture, and antimicrobial therapy tailored to culture and susceptibility data [<a href="#rid13">13-15</a>]. The need for hardware to maintain bone stability must be balanced with the potential impact of foreign material on propagation of infection. Additional factors influencing the approach include the microbiology of infection and individual patient circumstances.</p><p>Surgical management strategies include debridement with hardware retention or debridement with hardware removal. Hardware retention may be attempted when the stability of the bone and hardware construct would be compromised (such as in the case of fracture fixation hardware with unhealed fracture) or when there is a clear anatomic separation between the osteomyelitis and hardware. In contrast, hardware should be removed if the hardware is no longer needed for bone stability or if adequate debridement of the infected bone cannot be achieved with hardware retention.</p><p class="headingAnchor" id="H1527445286"><span class="h4">Antibiotic therapy</span><span class="headingEndMark"> — </span>The clinical approach to antibiotic therapy is discussed in this section; issues related to selection of antibiotic therapy are discussed below. (See <a class="local">'Antibiotic therapy'</a> below.)</p><p class="headingAnchor" id="H3556406458"><span class="h5">Retained hardware</span><span class="headingEndMark"> — </span>Patients with orthopedic hardware that is not amenable to removal and/or residual involved bone that is not amenable to complete debridement should be treated with a prolonged duration of intravenous antibiotic therapy (see <a class="local">'Antibiotic therapy'</a> below). The optimal duration is uncertain; most experts favor six weeks of therapy. While on parenteral antimicrobial therapy, patients should have weekly bloodwork for safety monitoring. (See <a class="local">'Monitoring during treatment'</a> below.)</p><p>Following completion of parenteral therapy with resolution of clinical signs of acute infection, patients with retained hardware and/or necrotic bone not amenable to debridement should receive long-term antibiotic suppression with an oral agent, guided by antimicrobial susceptibility data. Regimens for antibiotic suppression are summarized in the table. (See <a class="local">'Suppressive therapy'</a> below.)</p><p>In general, oral antimicrobial suppression should be continued until fractures are united. Once fracture healing is demonstrated radiographically, the timeframe for discontinuation of oral antimicrobial suppression should be determined carefully. Factors influencing the duration of therapy include the microbiology of infection, the duration of infection prior to debridement, the tolerability of the antimicrobial suppression regimen, the status of the orthopedic hardware (if present) at the site of infection, and individual patient circumstances.</p><p>Patients who would be unable to tolerate additional surgery in the setting of relapse may warrant antimicrobial suppression for as long as the hardware remains in place. However, the benefit of continuing suppressive treatment for longer than six months is uncertain. In one observational study including 89 patients with retained orthopedic hardware, use of suppressive antibiotics for at least three months after diagnosis was associated with being free of clinical infection (odds ratio 3.5; 95% CI 1.3-9.4), but use of suppressive antibiotic for at least six months after diagnosis was not [<a href="#rid16">16</a>].</p><p>Among patients who remain on antimicrobial suppression after fracture union, we discuss with the patient the benefits and adverse effects of ongoing suppression compared with discontinuing suppression. If hardware removal could be performed in the event of infection relapse (such as healed long-bone fracture), the infection appears to be well suppressed, and the patient is comfortable with the small possibility of further surgery, we offer discontinuation of suppression. If this small possibility of surgery is unacceptable, we continue suppression indefinitely.</p><p class="headingAnchor" id="H1608382449"><span class="h5">No retained hardware</span><span class="headingEndMark"> — </span>Patients with no retained hardware should complete a prolonged duration of intravenous or highly bioavailable oral antibiotic therapy (see <a class="local">'Antibiotic therapy'</a> below). Most experts favor continuing antimicrobial therapy at least until debrided bone has been covered by vascularized soft tissue, which is usually at least six weeks from the last debridement.</p><p>While on parenteral antimicrobial therapy, patients should have weekly bloodwork for safety monitoring. (See <a class="local">'Monitoring during treatment'</a> below.)</p><p class="headingAnchor" id="H546732797"><span class="h3">Monitoring during treatment</span><span class="headingEndMark"> — </span>Laboratory monitoring is needed during prolonged administration of antimicrobial therapy to monitor for adverse drug effects and to assess control of infection.</p><p>For patients on parenteral antimicrobial therapy, we obtain weekly complete blood count and chemistries. We obtain serum inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) at the beginning and end of parenteral therapy and at the time of transition to oral suppressive therapy (if used).</p><p>We do not routinely monitor weekly serum inflammatory markers during parenteral antimicrobial therapy. However, if there is clinical suspicion for treatment failure, we use inflammatory markers (in conjunction with clinical examination and radiographic studies such as magnetic resonance imaging or plain radiograph) to guide further management. </p><p>For patients on oral suppressive antimicrobial therapy, we obtain a complete blood count, creatinine, and alanine aminotransferase more frequently at the beginning and every 6 to 12 months thereafter. Suppressive antimicrobials with higher risk of adverse reactions (eg, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>) may require more frequent monitoring. </p><p class="headingAnchor" id="H1020970005"><span class="h3">Evaluation at the end of treatment</span><span class="headingEndMark"> — </span>Patients should undergo clinical evaluation at the end of the planned course of therapy. The site of infection should be examined for healing of the wound and soft tissue envelope. Patients should be questioned regarding systemic symptoms of infection as well as pain (type and severity). </p><p>We typically perform serum inflammatory markers (ESR and CRP), which are useful to confirm response to antimicrobial therapy as well as to serve as a new baseline for future evaluation. </p><p>We do not routinely perform radiographic imaging; frequently, residual inflammatory changes may be mistaken for persistent infection. The decision to pursue radiographic imaging should be guided by clinical suspicion for relapsing infection (as evidenced by worsening symptoms and/or rising inflammatory markers).</p><p>In the setting of persistently elevated inflammatory markers after completing a course of antibiotic therapy, the first priority should be to ensure that a thorough and complete debridement has been performed. In addition, the microbiologic diagnosis and susceptibility data should be reviewed.</p><p>Persistently elevated inflammatory markers two weeks following completion of antimicrobial therapy (without an alternative explanation) should prompt concern for persistent osteomyelitis [<a href="#rid17">17,18</a>]. Patients with associated symptoms warrant repeat debridement and additional antimicrobial therapy. In the absence of clinical signs consistent with persistent infection, clinical observation may be reasonable.</p><p class="headingAnchor" id="H252642003"><span class="h2">Hematogenous osteomyelitis</span><span class="headingEndMark"> — </span>In adults, hematogenous osteomyelitis most commonly involves the vertebral bones. Issues related to vertebral osteomyelitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults"</a>.)</p><p>Treatment of nonvertebral hematogenous osteomyelitis consists of parenteral antibiotics; in some circumstances, surgical debridement is also warranted. </p><p>In general, patients with infection confined to the medullary canal of the bone may be treated with antibiotics alone. Surgical debridement is warranted in patients with subperiosteal collection or abscess, necrotic bone, and/or in the setting of concomitant joint infection. Depending on the scope of the debridement, bone grafting or other orthopedic reconstruction may be required. A critical component of surgical management is adequate soft tissue coverage.</p><p>In all patients, blood cultures should be obtained prior to initiation of antibiotic therapy. If blood cultures are negative, a bone biopsy or aspirate of subperiosteal abscess for culture should be performed.</p><p>Empiric antibiotic coverage for treatment of hematogenous osteomyelitis should include activity against methicillin-resistant <em>Staphylococcus aureus</em> and aerobic gram-negative bacilli. An appropriate regimen consists of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and a third- or fourth-generation cephalosporin. (See <a class="local">'Antibiotic therapy'</a> below.)</p><p>Once an etiologic organism is isolated, the antibiotic regimen should be tailored to susceptibility data [<a href="#rid19">19</a>].</p><p>The optimal duration of antibiotic therapy for treatment of hematogenous (nonvertebral) osteomyelitis is uncertain. In general, at least four weeks of parenteral therapy from the last major debridement (if performed) are warranted. </p><p>For patients on parenteral antimicrobial therapy, we obtain weekly complete blood count and chemistries. In addition, we obtain serum inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) at the beginning and end of parenteral therapy and at the time of transition to oral suppressive therapy (if used).</p><p class="headingAnchor" id="H1380818423"><span class="h1">ANTIBIOTIC THERAPY</span><span class="headingEndMark"> — </span>Whenever possible, initiation of antibiotic therapy should be delayed until bone cultures can be obtained. Patients who have received antibiotics recently and do not have an acute need for surgical intervention should discontinue antibiotics for at least two weeks prior to debridement to optimize microbiologic diagnosis.</p><p>Suggested antibiotic regimens are outlined in the table  (<a class="graphic graphic_table graphicRef121445" data-inline-graphics="121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid20">20-25</a>]. Antibiotic therapy should be tailored to culture and susceptibility findings when available.</p><p class="headingAnchor" id="H458383639"><span class="h2">Systemic therapy</span><span class="headingEndMark"> — </span>Management of complex orthopedic infections usually includes a prolonged course of intravenous (IV) antibiotic therapy; data regarding use of oral antibiotic therapy are emerging. </p><p>In one randomized trial including more than 1000 patients with bone or joint infection treated with IV or oral antibiotic therapy for at least six weeks (median duration of therapy 78 and 71 days, respectively), the rates of treatment failure within one year were comparable (14 versus 13 percent) [<a href="#rid26">26</a>]. A variety of orthopedic infections were included, including osteomyelitis with or without an associated implant; surgical debridement occurred in 92 percent of cases. Based on these data, among carefully selected patients who undergo surgical debridement and have infection caused by an organism that is susceptible to oral therapy, a course of oral antimicrobial therapy (preferably with highly bioavailable agents, perhaps with extended duration up 12 weeks) may be a reasonable consideration in some circumstances. Subsequent to the publication of this trial, there is a report of the implementation of the OVIVA trial findings in a single hospital [<a href="#rid27">27</a>]. We believe the generalizability of the findings in the original trial and subsequent studies continue to be limited by the heterogeneous patient population and open-label design, so the results should be interpreted carefully when applied to individual patients [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H526904988"><span class="h3">Empiric therapy</span><span class="headingEndMark"> — </span>Empiric treatment of osteomyelitis should consist of antimicrobial therapy with activity against methicillin-resistant <em>S. aureus</em> (MRSA) and gram-negative organisms. Reasonable regimens include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> in combination with a third- or fourth-generation cephalosporin. We avoid combined use of vancomycin with <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, given the risk of nephrotoxicity with this combination [<a href="#rid30">30</a>]. Antibiotic therapy should be tailored to culture and susceptibility data when available.</p><p class="headingAnchor" id="H3423435795"><span class="h3">Definitive therapy</span></p><p class="headingAnchor" id="H2928444398"><span class="h4">Staphylococci</span></p><p class="headingAnchor" id="H3136351818"><span class="h5">Staphylococcus aureus</span><span class="headingEndMark"> — </span>In general, definitive therapy for treatment of osteomyelitis due to <em>S. aureus</em> consists of parenteral antibiotic therapy; regimens are summarized in the table  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>). In addition, use of adjunctive agents for treatment of <em>S. aureus</em> osteomyelitis may be warranted in some circumstances. (See <a class="local">'Use of adjunctive agents'</a> below.)</p><p>Antibiotics for treatment of osteomyelitis due to methicillin-susceptible <em>S. aureus</em> (MSSA) include <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, and <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>). Use of <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> for treatment of staphylococcal osteomyelitis is not universally accepted; in our practice, we use it as an alternative regimen for isolates with oxacillin minimum inhibitory concentration &lt;0.5 mcg/mL in the absence of concomitant bacteremia, since once-daily dosing is a convenient outpatient regimen [<a href="#rid31">31,32</a>]. Issues related to duration of antibiotic therapy are discussed above. (See <a class="local">'Clinical approach'</a> above.)</p><p>The antibiotic of choice for treatment of osteomyelitis due to MRSA is <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>); it is the antibiotic agent for which there is the greatest cumulative clinical experience, although there are no controlled trials [<a href="#rid33">33,34</a>]. The Infectious Diseases Society of America (IDSA) guidelines recommend a minimum of eight weeks of antibiotic therapy for treatment of MRSA osteomyelitis [<a href="#rid33">33</a>]; we favor a six-week course of therapy if adequate debridement has been performed. (See <a class="local">'Clinical approach'</a> above.)</p><p>Acceptable alternative agents to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of osteomyelitis due to MRSA include <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (and teicoplanin, where available) [<a href="#rid35">35-37</a>]. An observational study including more than 400 patients with osteomyelitis due to gram-positive pathogens noted success rates of 80 percent with daptomycin for treatment of staphylococcal osteomyelitis [<a href="#rid37">37</a>]. The optimal dosing of daptomycin for treatment of osteomyelitis is uncertain; dosing used in the preceding study ranged from 6 to 10 mg/kg/day.</p><p>Antibiotic agents that warrant further study for treatment of staphylococcal osteomyelitis include <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>, <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a>, and <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">dalbavancin</a> [<a href="#rid38">38-44</a>]. Ceftaroline has been used successfully for treatment of osteomyelitis but has been associated with increased risk of neutropenia [<a href="#rid39">39,45</a>]. Pending further study, use of ceftaroline should be reserved for patients unable to receive other therapies [<a href="#rid39">39</a>]. Ceftaroline susceptibility must be confirmed; the prevalence of resistance is high in some regions [<a href="#rid46">46</a>]. Use of telavancin for treatment of osteomyelitis should be deferred pending further study to evaluate safety, given increased risk of adverse events observed with its use for treatment of other conditions [<a href="#rid38">38,40,47</a>]. Dalbavancin has the unique advantage of weekly intravenous dosing [<a href="#rid41">41</a>]. It has been used successfully for treatment of osteomyelitis, but should be reserved for use in patients in whom other therapies are not an option and in whom the organism is susceptible, until further data are available [<a href="#rid41">41-44,48</a>].</p><p>We do not favor use of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, fluoroquinolones, <a class="drug drug_general" data-topicid="9515" href="/z/d/drug information/9515.html" rel="external">quinupristin-dalfopristin</a>, or <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> for definitive therapy of osteomyelitis due to <em>S. aureus</em>. A regimen of trimethoprim-sulfamethoxazole with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is advocated in some treatment guidelines [<a href="#rid33">33</a>] but not others [<a href="#rid49">49</a>]; data to support its use are limited [<a href="#rid18">18,50,51</a>]. Prolonged use of linezolid is limited by bone marrow toxicity, peripheral and optic neuropathy, lactic acidosis, and drug-drug interactions [<a href="#rid52">52-54</a>]. Tedizolid has not been studied sufficiently in osteomyelitis. Prolonged use of clindamycin has been associated with antibiotic-associated diarrhea and <em>Clostridioides</em> <em>difficile</em> infection. Fluoroquinolones have good bone penetration but are associated with inducible resistance to <em>S. aureus</em> when used as monotherapy.</p><p class="headingAnchor" id="H1714683307"><span class="h5">Coagulase-negative staphylococci</span><span class="headingEndMark"> — </span>Most coagulase-negative staphylococci are methicillin resistant (an exception is <em>Staphylococcus lugdunensis</em>, which is almost universally methicillin susceptible). (See  <a class="medical medical_review" href="/z/d/html/3155.html" rel="external">"Staphylococcus lugdunensis"</a>.)</p><p>Empiric treatment for osteomyelitis due to coagulase-negative staphylococci should consists of an agent with activity against methicillin-resistant staphylococci. If susceptibility testing demonstrates methicillin susceptibility, a beta-lactam with activity against methicillin-susceptible staphylococci should be used  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>).</p><p>In addition, use of adjunctive agents for treatment staphylococcal osteomyelitis may be warranted in some circumstances. (See <a class="local">'Use of adjunctive agents'</a> below.)</p><p class="headingAnchor" id="H3996281671"><span class="h5">Use of adjunctive agents</span><span class="headingEndMark"> — </span>Agents that may be used adjunctively in the setting of definitive therapy for treatment of staphylococcal osteomyelitis include <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a>.</p><p>We are in agreement with some experts who favor use of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (in combination with at least one other anti-staphylococcal agent) for its activity against microorganisms in biofilms, given the importance of biofilms in the pathophysiology of staphylococcal osteomyelitis (particularly in the setting of hardware) [<a href="#rid33">33,55,56</a>]. However, others oppose use of adjunctive rifampin given limited evidence for improved outcomes over standard antimicrobial therapy.</p><p>Clinical circumstances in which <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> may be most useful include osteomyelitis in the setting of prosthetic material and osteomyelitis in which therapeutic options are limited. Data may be extrapolated from literature on treatment of prosthetic joint infection to support use of rifampin in the treatment of infections involving other types of orthopedic hardware [<a href="#rid57">57,58</a>]. Use of rifampin must be weighed against the likelihood of toxicity and drug interactions [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Debridement and retention of prosthesis'</a>.)</p><p>We do not use other rifamycins (eg, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>) routinely in the setting of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> intolerance. In vitro and in vivo data are promising; clinical trials are warranted [<a href="#rid60">60,61</a>].</p><p><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> must be combined with another active antibacterial agent because rapid emergence of resistance in the setting of rifampin monotherapy is common. Rifampin should be initiated several days after surgical debridement; resistance is less likely to emerge when the burden of organisms has been reduced [<a href="#rid56">56,62</a>]. We continue rifampin for the duration of definitive therapy (parenteral therapy or highly bioavailable oral antibiotic therapy). [<a href="#rid56">56</a>]. We do not use rifampin during suppressive therapy. (See  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)"</a> and  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p><a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">Fusidic acid</a> (not available in the United States) may be used as adjunctive oral therapy in the treatment of chronic osteomyelitis [<a href="#rid63">63-65</a>].</p><p class="headingAnchor" id="H325709280"><span class="h4">Gram-negative organisms</span><span class="headingEndMark"> — </span>For treatment of osteomyelitis due to gram-negative organisms, we favor fluoroquinolones (if susceptibility testing confirms sensitivity) since they have high bone penetration with oral administration [<a href="#rid25">25,66</a>]. However, some avoid use of these agents in the setting of fracture, due to possible adverse effects on fracture healing [<a href="#rid66">66</a>].</p><p>Other antibiotics for treatment of osteomyelitis due to gram-negative organisms include parenteral beta-lactams and carbapenems. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>).</p><p>Among the gram-negative organisms, management of osteomyelitis caused by <em>Pseudomonas aeruginosa</em> may be more difficult than other organisms [<a href="#rid67">67,68</a>]. In one cohort study including 66 patients with osteomyelitis due to <em>P. aeruginosa</em> who underwent surgical debridement, most patients were treated with two weeks of intravenous therapy followed by oral fluoroquinolone therapy (median duration of treatment 45 days); clearance of infection was demonstrated in 94 percent of cases [<a href="#rid68">68</a>]. Most patients received monotherapy; no emergence of resistance was observed.</p><p class="headingAnchor" id="H3070285057"><span class="h4">Streptococci and enterococci</span><span class="headingEndMark"> — </span>Osteomyelitis due to penicillin-susceptible streptococci may be treated with penicillin; <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> is also acceptable and is more convenient for outpatient administration  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>).</p><p>For treatment of osteomyelitis due to enterococci, it is unclear whether combination therapy is superior to monotherapy, particularly if thorough debridement is performed [<a href="#rid69">69</a>]. We favor combination therapy in the setting of retained hardware; the regimen of <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> is generally well tolerated [<a href="#rid70">70</a>]. However, if antibiotic-impregnated material containing <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is implanted at the time of debridement, monotherapy is likely sufficient; in such cases, we favor treatment with intravenous ampicillin or penicillin  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2398167181"><span class="h3">Suppressive therapy</span><span class="headingEndMark"> — </span>Long-term antibiotic suppression with an oral agent is warranted for patients with retained hardware and/or necrotic bone not amenable to debridement, following completion of parenteral therapy with resolution of clinical signs of acute infection  (<a class="graphic graphic_table graphicRef119913" data-inline-graphics="119913" href="/z/d/graphic/119913.html" rel="external">table 2</a>). (See <a class="local">'Retained hardware'</a> above.)</p><p class="headingAnchor" id="H716626549"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>Issues related to duration of antibiotic therapy are discussed above. (See <a class="local">'Clinical approach'</a> above.)</p><p class="headingAnchor" id="H335046709"><span class="h2">Local antibiotic delivery</span><span class="headingEndMark"> — </span>Local antimicrobials mixed with absorbable carriers (eg, calcium sulfate beads) or nonabsorbable carriers (eg, polymethyl methacrylate beads or cement) placed in and around the fracture site may be useful as an adjunct to systemic antibiotics for prevention or treatment of infection [<a href="#rid71">71,72</a>].</p><p>Data are most robust for polymethylmethacrylate beads; these are typically removed within two to four weeks. Antibiotic-impregnated calcium sulfate beads are absorbable; they have been used as a bone substitute and delivery system for antibiotics repairing bony defects in open fractures caused by combat-related injuries [<a href="#rid71">71,73</a>].</p><p class="headingAnchor" id="H2108455663"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2350912530"><span class="h2">Osteomyelitis associated with trauma</span><span class="headingEndMark"> — </span>Issues related to osteomyelitis associated with trauma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7659.html" rel="external">"Osteomyelitis associated with open fractures in adults"</a>.)</p><p class="headingAnchor" id="H2082102530"><span class="h2">Prosthetic joint infection</span><span class="headingEndMark"> — </span>Issues related to prosthetic joint infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p class="headingAnchor" id="H4233253839"><span class="h2">Osteomyelitis in sickle cell disease</span><span class="headingEndMark"> — </span>Issues related to osteomyelitis in sickle cell disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5919.html" rel="external">"Acute and chronic bone complications of sickle cell disease", section on 'Osteomyelitis and septic arthritis'</a>.)</p><p class="headingAnchor" id="H3813732479"><span class="h1">ADJUNCTIVE THERAPIES</span><span class="headingEndMark"> — </span>Hyperbaric oxygen (HBO) has been suggested as an adjunctive therapy in patients with refractory osteomyelitis [<a href="#rid74">74,75</a>]. We do not favor use of HBO for treatment of osteomyelitis, given lack of sufficient data.</p><p>Issues related to HBO are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/326.html" rel="external">"Hyperbaric oxygen therapy"</a>.)</p><p class="headingAnchor" id="H3230632459"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Success rates for treatment of osteomyelitis reported in the literature range from 60 to 90 percent [<a href="#rid18">18</a>]. The success rate can be highly variable given the heterogeneity in completeness of debridement, the possibility of concomitant vascular insufficiency at the site of infection, and other factors.</p><p class="headingAnchor" id="H1137074048"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112039.html" rel="external">"Society guideline links: Osteomyelitis and prosthetic joint infection in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/121914.html" rel="external">"Society guideline links: Outpatient parenteral antimicrobial therapy"</a>.)</p><p class="headingAnchor" id="H2285218649"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment of nonhematogenous osteomyelitis</strong> – In general, management of nonhematogenous osteomyelitis consists of operative debridement for removal of necrotic material and culture of involved tissue and bone, followed by antimicrobial therapy for eradication of infection. (See <a class="local">'Nonhematogenous osteomyelitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without orthopedic hardware</strong> (see <a class="local">'Absence of orthopedic hardware'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with residual infected bone that is not amenable to complete removal are typically treated with a prolonged duration antibiotic therapy, guided by antimicrobial susceptibility data  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>). The optimal duration of antibiotic therapy is uncertain; we generally provide at least six weeks from the last debridement. (See <a class="local">'Residual infected bone present'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who undergo amputation or complete removal of all involved bone warrant a relatively short course of antibiotic therapy. (See <a class="local">'No residual infected bone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with orthopedic hardware</strong> (see <a class="local">'Presence of orthopedic hardware'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Following debridement, patients should be treated with a prolonged duration of intravenous antibiotic therapy, guided by antimicrobial susceptibility data  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>). The optimal duration is uncertain; we generally provide six weeks of therapy. (See <a class="local">'No retained hardware'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Thereafter, patients with retained hardware and/or necrotic bone not amenable to debridement are often treated with long-term antibiotic suppression with an oral agent, guided by antimicrobial susceptibility data  (<a class="graphic graphic_table graphicRef119913" href="/z/d/graphic/119913.html" rel="external">table 2</a>). (See <a class="local">'Retained hardware'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection for nonhematogenous osteomyelitis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric antibiotic therapy</strong> – We suggest empiric treatment of nonhematogenous osteomyelitis with antibiotics that have activity against methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and gram-negative organisms (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Reasonable regimens include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> in combination with a third- or fourth-generation cephalosporin. (See <a class="local">'Empiric therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Directed therapy</strong> – Once a pathogen has been identified from culture, antibiotic therapy should be tailored to the specific organism  (<a class="graphic graphic_table graphicRef121445" href="/z/d/graphic/121445.html" rel="external">table 1</a>). (See <a class="local">'Definitive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of </strong><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> – For patients with methicillin-sensitive or methicillin-resistant <em>S. aureus </em>osteomyelitis and retained hardware, we suggest adjunctive use of rifampin (in combination with at least one other anti-staphylococcal agent) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Use of rifampin must be weighed against the likelihood of toxicity and drug interactions. (See <a class="local">'Use of adjunctive agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematogenous osteomyelitis</strong> – Treatment of hematogenous (nonvertebral) osteomyelitis consists of parenteral antibiotic therapy. In addition, surgical debridement is warranted in the setting of subperiosteal collection and/or in the setting of concomitant joint infection. Empiric antibiotic coverage for treatment of hematogenous osteomyelitis should include activity against MRSA and aerobic gram-negative bacilli. Once an etiologic organism is isolated, the antibiotic regimen should be tailored to susceptibility data. The optimal duration of antibiotic therapy is uncertain; in general, parenteral therapy is continued for at least four weeks from the last major debridement. (See <a class="local">'Hematogenous osteomyelitis'</a> above.)</p><p></p><p class="headingAnchor" id="H544257438"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Tahaniyat Lalani, MBBS, MHS, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia 2008; 51:962.</a></li><li><a class="nounderline abstract_t">Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 2008; 31:637.</a></li><li><a class="nounderline abstract_t">Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015; 38:302.</a></li><li><a class="nounderline abstract_t">Lázaro-Martínez JL, Aragón-Sánchez J, García-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care 2014; 37:789.</a></li><li><a class="nounderline abstract_t">Zhang Y, Wang S, Liu M, et al. Adjunctive rifampin therapy for diabetic foot osteomyelitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020; 99:e20375.</a></li><li><a class="nounderline abstract_t">Wilson BM, Bessesen MT, Doros G, et al. Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration. JAMA Netw Open 2019; 2:e1916003.</a></li><li><a class="nounderline abstract_t">Bessesen MT, Doros G, Henrie AM, et al. A multicenter randomized placebo controlled trial of rifampin to reduce pedal amputations for osteomyelitis in veterans with diabetes (VA INTREPID). BMC Infect Dis 2020; 20:23.</a></li><li><a class="nounderline abstract_t">Schmitt SK. Osteomyelitis. Infect Dis Clin North Am 2017; 31:325.</a></li><li><a class="nounderline abstract_t">Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 2000; 30:205.</a></li><li><a class="nounderline abstract_t">Gariani K, Pham TT, Kressmann B, et al. Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial. Clin Infect Dis 2021; 73:e1539.</a></li><li><a class="nounderline abstract_t">Motaganahalli S, Batrouney A, Perera D, et al. Retrospective study of outcomes of short versus long duration of antibiotic therapy for residual osteomyelitis in surgically resected diabetic foot infection. J Antimicrob Chemother 2022; 78:284.</a></li><li><a class="nounderline abstract_t">Haug F, Waibel FWA, Lisy M, et al. The impact of the length of total and intravenous systemic antibiotic therapy for the remission of diabetic foot infections. Int J Infect Dis 2022; 120:179.</a></li><li><a class="nounderline abstract_t">Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006; 37 Suppl 2:S59.</a></li><li><a class="nounderline abstract_t">Weber EJ. Plantar puncture wounds: a survey to determine the incidence of infection. J Accid Emerg Med 1996; 13:274.</a></li><li><a class="nounderline abstract_t">Roesgen M, Hierholzer G, Hax PM. Post-traumatic osteomyelitis. Pathophysiology and management. Arch Orthop Trauma Surg 1989; 108:1.</a></li><li><a class="nounderline abstract_t">Keller SC, Cosgrove SE, Higgins Y, et al. Role of Suppressive Oral Antibiotics in Orthopedic Hardware Infections for Those Not Undergoing Two-Stage Replacement Surgery. Open Forum Infect Dis 2016; 3:ofw176.</a></li><li><a class="nounderline abstract_t">Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect 2008; 57:110.</a></li><li><a class="nounderline abstract_t">Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54:393.</a></li><li><a class="nounderline abstract_t">Ericsson HM, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol 1971; 217:Suppl 217:1+.</a></li><li><a class="nounderline abstract_t">Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am 1990; 72:104.</a></li><li><a class="nounderline abstract_t">Davey PG, Rowley DR, Phillips GA. Teicoplanin--home therapy for prosthetic joint infections. Eur J Surg Suppl 1992; :23.</a></li><li><a class="nounderline abstract_t">Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9:127.</a></li><li><a class="nounderline abstract_t">Black J, Hunt TL, Godley PJ, Matthew E. Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. J Infect Dis 1987; 155:968.</a></li><li><a class="nounderline abstract_t">Gentry LO, Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991; 35:538.</a></li><li><a class="nounderline abstract_t">Lew DP, Waldvogel FA. Quinolones and osteomyelitis: state-of-the-art. Drugs 1995; 49 Suppl 2:100.</a></li><li><a class="nounderline abstract_t">Li HK, Rombach I, Zambellas R, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med 2019; 380:425.</a></li><li><a class="nounderline abstract_t">Azamgarhi T, Shah A, Warren S. Clinical Experience of Implementing Oral Versus Intravenous Antibiotics (OVIVA) in a Specialist Orthopedic Hospital. Clin Infect Dis 2021; 73:e2582.</a></li><li><a class="nounderline abstract_t">Seidelman J, Sexton DJ. Is Long-term Oral Therapy for Treatment of Bone and Joint Infections Ready for Prime Time? Clin Infect Dis 2021; 73:e2589.</a></li><li><a class="nounderline abstract_t">Marks M, Bell LCK, Jones I, et al. Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2020; 71:207.</a></li><li><a class="nounderline abstract_t">Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Crit Care Med 2018; 46:12.</a></li><li><a class="nounderline abstract_t">Wieland BW, Marcantoni JR, Bommarito KM, et al. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2012; 54:585.</a></li><li><a class="nounderline abstract_t">Sharff K, Graber CJ, Spindel SJ, Nguyen HM. Ceftriaxone for Methicillin-Sensitive Staphylococcus aureus Osteoarticular Infections: A Survey of Infectious Disease Physicians’ Attitudes and Review of the Literature. Infect Dis Clin Pract (Baltim Md) 2014; 22:132.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53:928.</a></li><li><a class="nounderline abstract_t">Lalani T, Boucher HW, Cosgrove SE, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61:177.</a></li><li><a class="nounderline abstract_t">Moenster RP, Linneman TW, Finnegan PM, McDonald JR. Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Clin Ther 2012; 34:1521.</a></li><li><a class="nounderline abstract_t">Malizos K, Sarma J, Seaton RA, et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35:111.</a></li><li><a class="nounderline abstract_t">Harting J, Fernandez F, Kelley R, et al. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. Diagn Microbiol Infect Dis 2017; 89:294.</a></li><li><a class="nounderline abstract_t">Lalikian K, Parsiani R, Won R, et al. Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series. J Chemother 2018; 30:124.</a></li><li><a class="nounderline abstract_t">Schroeder CP, Van Anglen LJ, Dretler RH, et al. Outpatient treatment of osteomyelitis with telavancin. Int J Antimicrob Agents 2017; 50:93.</a></li><li><a class="nounderline abstract_t">Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. Open Forum Infect Dis 2019; 6:ofy331.</a></li><li><a class="nounderline abstract_t">Morata L, Cobo J, Fernández-Sampedro M, et al. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Almangour TA, Perry GK, Terriff CM, et al. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. Diagn Microbiol Infect Dis 2019; 93:213.</a></li><li><a class="nounderline abstract_t">Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis 2019; 81:210.</a></li><li><a class="nounderline abstract_t">Turner RB, Wilson DE, Saedi-Kwon H, et al. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline. J Antimicrob Chemother 2018; 73:772.</a></li><li><a class="nounderline abstract_t">Abbott IJ, Jenney AW, Jeremiah CJ, et al. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia. Antimicrob Agents Chemother 2015; 59:7837.</a></li><li><a class="nounderline abstract_t">Chuan J, Zhang Y, He X, et al. Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer? Front Pharmacol 2016; 7:330.</a></li><li><a class="nounderline abstract_t">Cain AR, Bremmer DN, Carr DR, et al. Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis. Open Forum Infect Dis 2022; 9:ofab589.</a></li><li><a class="nounderline abstract_t">Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis 2015; 61:e26.</a></li><li><a class="nounderline abstract_t">Euba G, Murillo O, Fernández-Sabé N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009; 53:2672.</a></li><li><a class="nounderline abstract_t">Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15:1163.</a></li><li><a class="nounderline abstract_t">Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59:173.</a></li><li><a class="nounderline abstract_t">Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155.</a></li><li><a class="nounderline abstract_t">Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55:387.</a></li><li><a class="nounderline abstract_t">Henry NK, Rouse MS, Whitesell AL, et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82:73.</a></li><li><a class="nounderline abstract_t">Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537.</a></li><li><a class="nounderline abstract_t">El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29:961.</a></li><li><a class="nounderline abstract_t">Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2013; 56:182.</a></li><li><a class="nounderline abstract_t">Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.</a></li><li><a class="nounderline abstract_t">Albano M, Karau MJ, Greenwood-Quaintance KE, et al. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Karau MJ, Schmidt-Malan SM, Albano M, et al. Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis. J Infect Dis 2020; 222:1498.</a></li><li><a class="nounderline abstract_t">Norden CW, Bryant R, Palmer D, et al. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986; 79:947.</a></li><li><a class="nounderline abstract_t">Howden BP, Grayson ML. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42:394.</a></li><li><a class="nounderline abstract_t">Pushkin R, Iglesias-Ussel MD, Keedy K, et al. A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction. Clin Infect Dis 2016; 63:1599.</a></li><li><a class="nounderline abstract_t">Marsot A, Ménard A, Dupouey J, et al. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. Br J Clin Pharmacol 2017; 83:1039.</a></li><li><a class="nounderline abstract_t">Huddleston PM, Steckelberg JM, Hanssen AD, et al. Ciprofloxacin inhibition of experimental fracture healing. J Bone Joint Surg Am 2000; 82:161.</a></li><li><a class="nounderline abstract_t">Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990; 34:40.</a></li><li><a class="nounderline abstract_t">Laghmouche N, Compain F, Jannot AS, et al. Successful treatment of Pseudomonas aeruginosa osteomyelitis with antibiotic monotherapy of limited duration. J Infect 2017; 75:198.</a></li><li><a class="nounderline abstract_t">El Helou OC, Berbari EF, Marculescu CE, et al. Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? Clin Infect Dis 2008; 47:903.</a></li><li><a class="nounderline abstract_t">Euba G, Lora-Tamayo J, Murillo O, et al. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother 2009; 53:4305.</a></li><li><a class="nounderline abstract_t">Hake ME, Young H, Hak DJ, et al. Local antibiotic therapy strategies in orthopaedic trauma: Practical tips and tricks and review of the literature. Injury 2015; 46:1447.</a></li><li><a class="nounderline abstract_t">Sheridan GA, Falk DP, Fragomen AT, Rozbruch SR. Calcium sulfate in the management of osteomyelitis: A systematic review and meta-analysis of comparative studies. Medicine (Baltimore) 2022; 101:e31364.</a></li><li><a class="nounderline abstract_t">Helgeson MD, Potter BK, Tucker CJ, et al. Antibiotic-impregnated calcium sulfate use in combat-related open fractures. Orthopedics 2009; 32:323.</a></li><li><a class="nounderline abstract_t">Mader JT, Guckian JC, Glass DL, Reinarz JA. Therapy with hyperbaric oxygen for experimental osteomyelitis due to Staphylococcus aureus in rabbits. J Infect Dis 1978; 138:312.</a></li><li><a class="nounderline abstract_t">Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. PM R 2009; 1:471.</a></li></ol></div><div id="topicVersionRevision">Topic 114350 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385975" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primarily non-surgical management of osteomyelitis of the foot in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184898" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25414157" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130347" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32481422" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adjunctive rifampin therapy for diabetic foot osteomyelitis: A protocol for systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31755948" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31914940" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A multicenter randomized placebo controlled trial of rifampin to reduce pedal amputations for osteomyelitis in veterans with diabetes (VA INTREPID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483044" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619757" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ceftriaxone therapy for staphylococcal osteomyelitis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33242083" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36418157" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Retrospective study of outcomes of short versus long duration of antibiotic therapy for residual osteomyelitis in surgically resected diabetic foot infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35358726" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The impact of the length of total and intravenous systemic antibiotic therapy for the remission of diabetic foot infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651073" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnosis and treatment of infections associated with fracture-fixation devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8832349" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Plantar puncture wounds: a survey to determine the incidence of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643936" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Post-traumatic osteomyelitis. Pathophysiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27747252" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of Suppressive Oral Antibiotics in Orthopedic Hardware Infections for Those Not Undergoing Two-Stage Replacement Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18533269" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157324" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Systemic antibiotic therapy for chronic osteomyelitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4325956" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibiotic sensitivity testing. Report of an international collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2295657" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381637" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Teicoplanin--home therapy for prosthetic joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840453" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3494088" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039205" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ofloxacin versus parenteral therapy for chronic osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549277" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Quinolones and osteomyelitis: state-of-the-art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30699315" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oral versus Intravenous Antibiotics for Bone and Joint Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926108" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical Experience of Implementing Oral Versus Intravenous Antibiotics (OVIVA) in a Specialist Orthopedic Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926118" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Is Long-term Oral Therapy for Treatment of Bone and Joint Infections Ready for Prime Time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31603189" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29088001" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22144536" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ceftriaxone for Methicillin-Sensitive Staphylococcus aureus Osteoarticular Infections: A Survey of Infectious Disease Physicians’Attitudes and Review of the Literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117932" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antibiotic treatment of gram-positive bone and joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999973" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748973" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563898" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29137718" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28697650" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28456704" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Outpatient treatment of osteomyelitis with telavancin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30648126" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858217" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30396697" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30794940" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29237024" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392488" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27721793" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35071682" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26229122" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307354" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438638" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17574788" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982292" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705640" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Linezolid in the treatment of Gram-positive prosthetic joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578332" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605897" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505968" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942204" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443255" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31451499" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32914837" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3526570" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16392088" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682068" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27813241" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10682725" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ciprofloxacin inhibition of experimental fracture healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2183710" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28668598" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful treatment of Pseudomonas aeruginosa osteomyelitis with antibiotic monotherapy of limited duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18754743" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667290" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26007616" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Local antibiotic therapy strategies in orthopaedic trauma: Practical tips and tricks and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36397437" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Calcium sulfate in the management of osteomyelitis: A systematic review and meta-analysis of comparative studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19472965" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antibiotic-impregnated calcium sulfate use in combat-related open fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/701849" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Therapy with hyperbaric oxygen for experimental osteomyelitis due to Staphylococcus aureus in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19627935" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
